Oncorus
2015
FOUNDED
PRIVATE
STATUS
Series B
LATEST DEAL TYPE
$89.5M
LATEST DEAL AMOUNT
18
INVESTORS
Description
Developer of a next-generation immunotherapy platform intended to offer treatment of cancer. The company's platform develops innovative and impactful oncolytic products with unprecedented potential to recruit all arms of the immune system to treat solid tumors, enabling patients to have hope and impactful therapies to treat their cancer.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Primary Office
- 50 Hampshire Street
- Suite 401
- Cambridge, MA 02139
- United States
+1 (857) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Oncorus’s full profile, request a free trial.
Oncorus Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 20-Dec-2019 | $89.5M | 00000 | Completed | Generating Revenue | |
| 2. Early Stage VC (Series A2) | 15-Dec-2016 | 000.00 | 0000 | 000.00 | Completed | Generating Revenue |
| 1. Early Stage VC (Series A1) | 19-Jul-2016 | $37.2M | $37.2M | 000.00 | Completed | Generating Revenue |
Oncorus Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A-1 | 00,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
Oncorus Competitors (46)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Jounce Therapeutics | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
| 000000000 00000000 | Venture Capital-Backed | Ottawa, Canada | 00 | 00000 | 000000000000 | 00000 |
| 0000000 | Venture Capital-Backed | Houston, TX | 00 | 000.00 | 00000000000 | 000.00 |
| 0000 000000 | Formerly VC-backed | Santa Monica, CA | 000 | 00000 | 000000&0 | 00000 |
| 0000 000000000000 | Formerly VC-backed | Geneva, Switzerland | 000.00 | 000000&0 | 000.00 |
Oncorus Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Citadel (Hedge Fund) | Hedge Fund | Minority | 000 0000 | 000000 0 | ||
| Cowen Healthcare Investments | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Fosun Industrial Holdings | Corporation | Minority | 000 0000 | 000000 0 | ||
| IMM Investment | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Perceptive Advisors | Hedge Fund | Minority | 000 0000 | 000000 0 |
Oncorus Executive Team (9)
4 Former Executives
You’re viewing 5 of 9 executives. Get the full list »Oncorus Board Members (9)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Alon Lazarus Ph.D | Self | Board Member | 000 0000 | |
| Briggs Morrison MD | MPM Capital | Board Member | 000 0000 | |
| Cameron Wheeler Ph.D | Deerfield Management | Board Member | 000 0000 | |
| Luke Evnin Ph.D | MPM Capital | Board Member | 000 0000 | |
| Mary Fenton | Self | Board Member | 000 0000 |